Clinical Trial 24108
- Cancer Type: Malignant Hematology
- Study Type: Treatment
- NCT#: NCT07441694
- Phase: Phase I
- Principal Investigator: Kuykendall, Andrew
- 813-745-6100
- Or 1-800-679-0775
-
Overview
Study Title:
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Summary:
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Objective:
Primary Objective: To determine the safety, tolerability, DLTs, and MTD and/or RDE(s) of INCA036978 administered as monotherapy and in combination with ruxolitinib. Secondary Objectives: To determine the PK of INCA036978 administered as monotherapy or in combination with ruxolitinib. To determine the preliminary efficacy of INCA036978 administered as monotherapy and in combination with ruxolitinib.
-
Treatments
Therapies:
Fc-silent monoclonal antibody; JAK1 and JAK2 Protein Kinases Inhibitor
Medications:
INCA036978 (); Jakafi (Ruxolitinib); Ruxolitinib ()
-
Inclusion Criteria
- Key Inclusion Criteria:
- Life expectancy > 6 months.
- Willingness to undergo a pretreatment and limited on-study BM biopsies and aspirates (as appropriate to disease).
- Participants with MF, PV and ET as defined in the protocol.
-
Exclusion Criteria
- Key Exclusion Criteria:
- Presence of any hematological malignancy other than MF, PV, or ET.
- Malignancy within the last 3 years prior to enrollment.
- Acute or chronic HBV, Active HCV or known HIV or tuberculosis infection.
- Clinically significant or uncontrolled cardiac disease.
- Has undergone any prior allogeneic stem-cell transplantation or such transplantation is planned in the next 6 months.
- Laboratory values outside the Protocol-defined ranges.
- Prior history of major bleeding or thrombosis within the last 3 months prior to study enrollment.
- Presence of chronic or current active infectious disease requiring systemic treatment.
- Treatment with an MPN-directed therapy (approved or investigational) within the per protocol threshold before the administration of study drug.
- Prior radiation therapy within 28 days before the first dose of study treatment.
- Other protocol-defined Inclusion/Exclusion Criteria may apply.
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.